Literature DB >> 12805329

Simple clinical prognostic model for hepatocellular carcinoma in developing countries and its validation.

Chee Kiat Tan1, Ngai Moh Law, Han Seong Ng, David Machin.   

Abstract

PURPOSE: More than 80% of hepatocellular carcinomas (HCCs) worldwide occur in developing countries, especially in Asia. It often presents at an advanced stage beyond treatment. In this circumstance, a simple prognostic model is useful. Previous prognostic models require radiologic and laboratory investigations that are not readily available in developing countries. Our aim is to formulate and then validate a simple clinical prognostic model for HCC in an Asian population using only clinical parameters and with serum alpha-fetoprotein (AFP) as the sole laboratory test. PATIENTS AND METHODS: Cox regression modeling was performed on several clinical parameters and serum AFP level in 397 patients with HCC who received only supportive care in Singapore. A later group of 324 HCC patients from an Asia-Pacific-wide randomized trial was then used to validate the model.
RESULTS: Ascites, physical performance status, and serum AFP were independently predictive of survival. Cox analysis yielded a simple score based on these three variables that categorizes patients into low-, medium-, and high-risk groups with 6-month survivals of 43%, 21%, and 5%, respectively. The prospective validation data provided corresponding estimates of 33%, 15%, and 3% and give confirmation of the utility of the simple model.
CONCLUSION: We have formulated and prospectively validated a simple prognostic score for untreated HCC that only requires a clinical evaluation for ascites and physical performance status and measurement of serum AFP. This simple model is particularly apt for developing country circumstances and can also be used to select patients for treatment trials.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12805329     DOI: 10.1200/JCO.2003.03.151

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  19 in total

1.  Genetic variants in the KDR gene is associated with the prognosis of transarterial chemoembolization treated hepatocellular carcinoma.

Authors:  You-Bing Zheng; Jian-Wen Huang; Mei-Xiao Zhan; Wei Zhao; Bing Liu; Xu He; Yong Li; Bao-Shan Hu; Li-Gong Lu
Journal:  Tumour Biol       Date:  2014-08-16

2.  Neutrophil-lymphocyte ratio as a predictor of outcomes for patients with hepatocellular carcinoma undergoing TAE combined with Sorafenib.

Authors:  Kai Wei; Meng Wang; Wei Zhang; Han Mu; Tian-Qiang Song
Journal:  Med Oncol       Date:  2014-05-04       Impact factor: 3.064

3.  Effective hepatic artery chemoembolization for advanced hepatocellular carcinoma with multiple tumor thrombi and pulmonary metastases: A case report.

Authors:  De-Jia Huang; Yan-Hao Li; Yao-Chang Luo; Jun-Zhen Huang; Hai-Yuan He
Journal:  Oncol Lett       Date:  2016-07-12       Impact factor: 2.967

4.  Prognostic value of serum vascular endothelial growth factor receptor 2 response in patients with hepatocellular carcinoma undergoing transarterial chemoembolization.

Authors:  You-Bing Zheng; Qing-Wen Meng; Wei Zhao; Bing Liu; Jian-Wen Huang; Xu He; Yong Li; Bao-Shan Hu; Li-Gong Lu
Journal:  Med Oncol       Date:  2014-01-18       Impact factor: 3.064

5.  Is there any benefit from expanding the criteria for the resection of hepatocellular carcinoma in cirrhotic liver? Experience from a developing country.

Authors:  Danijel A Galun; Predrag Bulajic; Marinko Zuvela; Dragan Basaric; Tatjana Ille; Miroslav N Milicevic
Journal:  World J Surg       Date:  2012-07       Impact factor: 3.352

Review 6.  Hepatocellular carcinoma: From clinical practice to evidence-based treatment protocols.

Authors:  Danijel Galun; Dragan Basaric; Marinko Zuvela; Predrag Bulajic; Aleksandar Bogdanovic; Nemanja Bidzic; Miroslav Milicevic
Journal:  World J Hepatol       Date:  2015-09-18

Review 7.  Serum tumor markers for detection of hepatocellular carcinoma.

Authors:  Lin Zhou; Jia Liu; Feng Luo
Journal:  World J Gastroenterol       Date:  2006-02-28       Impact factor: 5.742

8.  Decoding human liver cancer signatures.

Authors:  Ju-Seog Lee
Journal:  Gastrointest Cancer Res       Date:  2008-07

9.  Prognostic factors of hepatocellular carcinoma patients treated by transarterial chemoembolization.

Authors:  Jun Xiao; Guojian Li; Shuhan Lin; Ke He; Hao Lai; Xianwei Mo; Jiansi Chen; Yuan Lin
Journal:  Int J Clin Exp Pathol       Date:  2014-02-15

Review 10.  Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies.

Authors:  Puneeta Tandon; Guadalupe Garcia-Tsao
Journal:  Liver Int       Date:  2008-12-24       Impact factor: 5.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.